Claims:

1. A compound of Formula I:

Formula I



or a pharmaceutically acceptable salt thereof, wherein: R_1 independently represents null,





R_2 independently represents


SH
O
H
H_3C
N
H
O
,

O
H_2N
HS
,

O
H
N
OH
,

O
HO
O
O
,

O
H
S
S
,

O
O
H
S
S
,

O
O
4
7
10
13
16
19
,


O
O
5
8
11
14
17
20


O
5
8
11
14
17
20


O
4
7
10
13
16
19


H
OH
HO
H
N
O
O


N
CH3
HO
OH
N
H
NHCOCH3
O











,



,



,



or



;

a is independently 2, 3, or 7;
each b is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, —OH, —OD, C_1—C_6-alkyl, —NH_2 or —$COCH_3$.

2. A compound of Formula Ia, a biologically active stereoisomer or enantiomer of Formula I:

Formula Ia



or a pharmaceutically acceptable salt thereof, wherein:

R_1 independently represents NULL,











or



R_2 independently represents















a is independently 2, 3, or 7;
each b is independently 3, 5 or 6;
e is independently 1, 2 or 6;
c and d are each independently H, D, —OH, —OD, C_1—C_6-alkyl, —NH_2 or —$COCH_3$.

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

5. A compound of claim 1, comprising Formula I: (S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl 5-((R)-1,2-dithiolan-3-yl)pentanoate; (S)-5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate.

6. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.